Tscan Therapeutics is trading 6.63% down at $0.30 in after-hours trading, amid broader risk-off market conditions.
- It closed at $0.32 on September 15, 2026.
- No new company-specific announcement was identified for September 15; the latest major disclosures were the September 2 strategic reorganization and September 8 executive retention program.
- Falling major indexes, elevated Treasury yields, and geopolitical and energy-related inflation concerns point to global-market pressure rather than a confirmed company catalyst.